medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-18-20-26medsovet-794Research ArticleКОГНИТИВНЫЕ РАССТРОЙСТВАCOGNITIVE DISRODERSПрофилактика и лечение болезни АльцгеймераHow to effectively treat migraine attacksПарфеновВ. А.ParfyonovV. A.noemail@neicon.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian Federation2014301220140182026Copyright © Парфенов В.А., 20142014Парфенов В.А.Parfyonov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/794

Представлен обзор литературных данных по профилактике и лечению болезни Альцгеймера (БА). Отмечается, что употребление в большом количестве свежих фруктов или овощей, средиземноморская диета, регулярные физические нагрузки и умственная активность сочетаются со снижением частоты развития БА. Профилактика инсульта расценивается как наиболее эффективное средство снижения риска развития БА и прогрессирования ее симптомов. Постепенная нормализация артериального давления у пациентов с артериальной гипертензией уменьшает риск возникновения различных типов деменций, включая БА. Отмечается эффективность ингибиторов центральной ацетилхолинэстеразы (донепезил, галантамин, ривастигмин) и мемантина в улучшении когнитивных функций, поведения и ежедневной активности. Приводятся результаты исследования ASCOMALVA, в котором показано, что у пациентов с БА, сочетающейся с цереброваскулярным заболеванием, добавление холина альфосцерата (Глиатилин) к донепезилу улучшает когнитивные функции и показатели ежедневной активности пациентов.

Migraine is one of the most common causes of disability of young and middle-aged people. Many patients with migraine are not satisfied with drugs used for the treatment. Rational approach to the treatment of migraine and effective relief of migraine attacks are discussed. Medicines for the treatment of migraine attacks and their evidence-based efficacy are analyzed. The efficacy and safety in relieving migraine of Excedrin containing 250 mg acetylsalicylic acid, 250 mg paracetamol and 65 mg caffeine, are described.

профилактика болезни Альцгеймералечение болезни Альцгеймераингибиторы центральной ацетилхолинэстеразымемантина гидрохлоридхолина аль-фосцератисследование ASCOMALVAmigrainepain medicationstriptansacetylsalicylic acidparacetamolcaffeineExcedrinReferencesCerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Edited by O'Brien J., Ames D., Gustafson L. ct al. Martin Dunitz-2004.Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Edited by O'Brien J., Ames D., Gustafson L. ct al. Martin Dunitz-2004.Яхно Н.Н., Захаров В.В., Локшина А.Б и др. Деменции. Руководство для врачей. М., 2011.Яхно Н.Н., Захаров В.В., Локшина А.Б и др. Деменции. Руководство для врачей. М., 2011.Reiman EM, Langbaum JBS, TarioP. N. Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med, 2010, 4: 3-14.Reiman EM, Langbaum JBS, TarioP. N. Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med, 2010, 4: 3-14.Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study Psychological Science, 2003, 14: 125-130.Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study Psychological Science, 2003, 14: 125-130.Larson EB, Wang L, Bowen JD et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Annals of Internal Medicine, 2006, 144: 73-81.Larson EB, Wang L, Bowen JD et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Annals of Internal Medicine, 2006, 144: 73-81.Barnes DE, Blackwell T, Stone KL et al. Cognition in older women: the importance of daytime movement. Journal of the American Geriatrics Society, 2008, 56: 1658-1664.Barnes DE, Blackwell T, Stone KL et al. Cognition in older women: the importance of daytime movement. Journal of the American Geriatrics Society, 2008, 56: 1658-1664.Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Brain Research Bulletin, 2006, 69: 1-19.Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Brain Research Bulletin, 2006, 69: 1-19.Morris MC, Evans DA, Tangney CC et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology, 2006, 67: 1370-1376.Morris MC, Evans DA, Tangney CC et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology, 2006, 67: 1370-1376.Scarmeas N, Stern Y, Mayeux R et al. Mediterranean diet and mild cognitive impairment. Arch Neurol, 2009, 66: 216-225.Scarmeas N, Stern Y, Mayeux R et al. Mediterranean diet and mild cognitive impairment. Arch Neurol, 2009, 66: 216-225.Larrieu S, Letenneur L, Helmer C, et al. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging, 2004, 8: 150-154.Larrieu S, Letenneur L, Helmer C, et al. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging, 2004, 8: 150-154.Wilson RS, Scherr PA, Schneider JA et al. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology, 2007, 69: 1911-1920.Wilson RS, Scherr PA, Schneider JA et al. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology, 2007, 69: 1911-1920.Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003, 290: 2015-2022.Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003, 290: 2015-2022.Gates N, Valenzuela M. Cognitive exercise and its role in cognitive function in older adults. Curr Psychiatry Rep, 2010, 12: 20-27.Gates N, Valenzuela M. Cognitive exercise and its role in cognitive function in older adults. Curr Psychiatry Rep, 2010, 12: 20-27.Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012.Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012.Patterson C, Feightner JW, Garcia A et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Canadian Medical Association Journal, 2008, 178: 548-556.Patterson C, Feightner JW, Garcia A et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Canadian Medical Association Journal, 2008, 178: 548-556.De Craen AJM, Gussekloo J, Vrijsen B, et al. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol, 2005, 161: 114-120.De Craen AJM, Gussekloo J, Vrijsen B, et al. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol, 2005, 161: 114-120.ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology, 2007, 68: 1800-1808.ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology, 2007, 68: 1800-1808.Nelson HD, Humphrey LL, Nygren P. et al. Postmenopausal hormone replacement therapy: scientific review. JAMA, 2002, 288: 872-881.Nelson HD, Humphrey LL, Nygren P. et al. Postmenopausal hormone replacement therapy: scientific review. JAMA, 2002, 288: 872-881.Shumaker SA, Legault C, Kuller L, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA, 2004, 291: 2947-2958.Shumaker SA, Legault C, Kuller L, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA, 2004, 291: 2947-2958.Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother, 2005, 39: 2073-2080.Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother, 2005, 39: 2073-2080.Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet, 2007, 369: 208-216.Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet, 2007, 369: 208-216.DeKosky ST, Williamson JD, Fitzpatrick AL et al.Ginkgo biloba for prevention of dementia: a randomized controlled trial.JAMA, 2008, 300: 2253-2262.DeKosky ST, Williamson JD, Fitzpatrick AL et al.Ginkgo biloba for prevention of dementia: a randomized controlled trial.JAMA, 2008, 300: 2253-2262.Vellas B, Coley N, Ousset PJ et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol., 2012, 11: 851-859.Vellas B, Coley N, Ousset PJ et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol., 2012, 11: 851-859.Panza F, Solfrizzi V, Frisardi V et al. Disease modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators [review]. Drugs Aging, 2009, 26(7): 537-555.Panza F, Solfrizzi V, Frisardi V et al. Disease modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators [review]. Drugs Aging, 2009, 26(7): 537-555.Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev., 2006 (1):CD005593.Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev., 2006 (1):CD005593.Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008, 148: 370-378.Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008, 148: 370-378.Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry, 1999, 14: 135-146.Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry, 1999, 14: 135-146.Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med, 2003, 348: 1333-1341.Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med, 2003, 348: 1333-1341.van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry, 2006, 14: 428-437.van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry, 2006, 14: 428-437.Grossberg GT, Pejovic V, Miller ML, Graham SM. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord., 2009, 27: 164-172.Grossberg GT, Pejovic V, Miller ML, Graham SM. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord., 2009, 27: 164-172.Wei Z-H, He Q-B, Wang H. et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatement of Alzheimer's disease. J Neural Transm, 2007, 3: 84-91.Wei Z-H, He Q-B, Wang H. et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatement of Alzheimer's disease. J Neural Transm, 2007, 3: 84-91.Plosker GL, Gautheir S. Cerebrolysin: a review of its use in dementia. Drugs Aging, 2009, 26: 893-915.Plosker GL, Gautheir S. Cerebrolysin: a review of its use in dementia. Drugs Aging, 2009, 26: 893-915.Weinmann S, Roll S, Schwarzbach C et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatrics, 2010, 10: 14.Weinmann S, Roll S, Schwarzbach C et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatrics, 2010, 10: 14.Schneider LS, Dagerman KS, Insel P. Risk of death with atypical drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 2005, 294: 1934-1943.Schneider LS, Dagerman KS, Insel P. Risk of death with atypical drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 2005, 294: 1934-1943.Ballard C, Hanney ML, Theodoulou M. et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol, 2009, 8: 151-157.Ballard C, Hanney ML, Theodoulou M. et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol, 2009, 8: 151-157.Weintraub D, Rosenberg PB, Drye LT et al. Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. Am J Geriatr Psychiatry, 2010, 18: 332-340.Weintraub D, Rosenberg PB, Drye LT et al. Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. Am J Geriatr Psychiatry, 2010, 18: 332-340.Scapicchio PL. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? Int JNeurosci, 2013, 123: 444-449.Scapicchio PL. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? Int JNeurosci, 2013, 123: 444-449.Traini E, Bramanti V, Amenta F Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent Curr Alzheimer Res, 2013, 10: 1070-1079.Traini E, Bramanti V, Amenta F Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent Curr Alzheimer Res, 2013, 10: 1070-1079.Amenta F, Carotenuto A, Fasanaro AM et al. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.J Alzheimers Dis., 2014, 42 (Suppl. 3): S281-288.Amenta F, Carotenuto A, Fasanaro AM et al. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.J Alzheimers Dis., 2014, 42 (Suppl. 3): S281-288.

The authors declare that there are no conflicts of interest present.